Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

[Prevalence and clinical characteristics of thyroid disease induced by chronic hepatitis B treated with polyethylene glycol (peg) interferon-alpha].

Chen XF, Chen XP, Ma XJ, Chen WL, Huang J, Luo XD.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012 Apr;26(2):117-9. Chinese.

PMID:
23002550
2.

[Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].

Kupś-Rzepecka J, Woźniakowska-Gesicka T, Gołabek V.

Przegl Lek. 2011;68(6):311-5. Polish.

PMID:
22039668
3.

Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B?

Kozielewicz D, Zaleśna A, Dybowska D.

Expert Opin Drug Saf. 2014 Aug;13(8):1009-14. doi: 10.1517/14740338.2014.921156. Epub 2014 Jun 14.

PMID:
24930451
4.

[A clinical study on leucogen tablets therapy efficacy during PEG-alpha interferon and alpha-interferon in chronic hepatitis B].

Zhang HF, Wang LM, Dong Y, Xu ZQ, Chen DW, Gan Y, Wang FC, Zhu SS.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012 Apr;26(2):111-3. Chinese.

PMID:
23002548
5.

[Thyroid dysfunction in patients with chronic hepatitis C treated with pegylated interferon alpha].

Montero-Tinnirello J, de la Fuente-Aguado J, Rodríguez-Pecci MS, Fernández-Fernández FJ.

Rev Clin Esp. 2011 Sep;211(8):436-8. doi: 10.1016/j.rce.2011.01.021. Epub 2011 May 4. Spanish. No abstract available.

PMID:
21546017
6.
7.

The incidence and evolution of thyroid dysfunction during interferon-alpha therapy in children with chronic hepatitis B infection.

Kuloglu Z, Kansu A, Berberoglu M, Adiyaman P, Ocal G, Girgin N.

J Pediatr Endocrinol Metab. 2007 Feb;20(2):237-45.

PMID:
17396441
8.
9.

Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.

Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J.

Arch Intern Med. 1998 Jul 13;158(13):1445-8.

PMID:
9665354
10.

The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C.

Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N.

Am J Gastroenterol. 1994 Mar;89(3):399-403.

PMID:
8122653
11.

The influence of interferon alpha on the induction of autoimmune thyroiditis in patients treated for chronic viral hepatitis type C.

Krupińska J, Wawrzynowicz-Syczewska M, Urbanowicz W, Pobłocki J, Syrenicz A.

Endokrynol Pol. 2011;62(6):517-22.

12.

Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.

Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY, Chang WY.

Eur J Endocrinol. 2000 May;142(5):431-7.

13.

Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy.

Marazuela M, García-Buey L, González-Fernández B, García-Monzón C, Arranz A, Borque MJ, Moreno-Otero R.

Clin Endocrinol (Oxf). 1996 Jun;44(6):635-42.

PMID:
8759175
14.

Prediction of interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.

Murakami T, Masumoto T, Michitaka K, Horiike N, Hino H, Okada S, Kitai K, Onji M.

J Gastroenterol Hepatol. 1995 Sep-Oct;10(5):528-31.

PMID:
8963028
15.

[Thyroid dysfunctions in patients with viral hepatitis treated with interferon-alpha].

Földes I, Dávid K, Horváth G, Osztrogonácz H, Jankovics K, Tolvaj G.

Orv Hetil. 2004 Jun 6;145(23):1211-6. Hungarian.

PMID:
15264588
16.

Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy.

Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S.

Hepatology. 1997 Jul;26(1):206-10.

PMID:
9214471
17.

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

Alsaran K, Sabry A, Shaheen N.

Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19.

PMID:
20490669
18.

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study [KULDS] Group.

J Gastroenterol Hepatol. 2012 Jul;27(7):1233-40. doi: 10.1111/j.1440-1746.2011.06965.x.

PMID:
22098185
19.

Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.

Keating GM.

Drugs. 2009;69(18):2633-60. doi: 10.2165/11203660-000000000-00000. Review.

PMID:
19943712
20.

Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C.

Vasiliadis T, Anagnostis P, Nalmpantidis G, Soufleris K, Patsiaoura K, Grammatikos N, Orfanou-Koumerkeridou E, Kargiotis K, Slavakis A, Deliyiannidis A, Eugenidis N.

Ann Acad Med Singapore. 2011 Sep;40(9):394-400. Erratum in: Ann Acad Med Singapore. 2011 Dec;40(12):558. [multiple author names corrected].

Items per page

Supplemental Content

Write to the Help Desk